A long way to go: caspase inhibitors in clinical use
- PMID: 34654807
- PMCID: PMC8519909
- DOI: 10.1038/s41419-021-04240-3
A long way to go: caspase inhibitors in clinical use
Abstract
Caspases are an evolutionary conserved family of cysteine-dependent proteases that are involved in many vital cellular processes including apoptosis, proliferation, differentiation and inflammatory response. Dysregulation of caspase-mediated apoptosis and inflammation has been linked to the pathogenesis of various diseases such as inflammatory diseases, neurological disorders, metabolic diseases, and cancer. Multiple caspase inhibitors have been designed and synthesized as a potential therapeutic tool for the treatment of cell death-related pathologies. However, only a few have progressed to clinical trials because of the consistent challenges faced amongst the different types of caspase inhibitors used for the treatment of the various pathologies, namely an inadequate efficacy, poor target specificity, or adverse side effects. Importantly, a large proportion of this failure lies in the lack of understanding various caspase functions. To overcome the current challenges, further studies on understanding caspase function in a disease model is a fundamental requirement to effectively develop their inhibitors as a treatment for the different pathologies. Therefore, the present review focuses on the descriptive properties and characteristics of caspase inhibitors known to date, and their therapeutic application in animal and clinical studies. In addition, a brief discussion on the achievements, and current challenges faced, are presented in support to providing more perspectives for further development of successful therapeutic caspase inhibitors for various diseases.
© 2021. The Author(s).
Conflict of interest statement
Authors declare the absence of any competing financial interests.
Figures
Similar articles
-
Pharmacological caspase inhibitors: research towards therapeutic perspectives.J Physiol Pharmacol. 2015 Aug;66(4):473-82. J Physiol Pharmacol. 2015. PMID: 26348072 Review.
-
Current opinion on 3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]- 4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid, an investigational drug targeting caspases and caspase-like proteases: the clinical trials in sight and recent anti-inflammatory advances.Recent Pat Inflamm Allergy Drug Discov. 2013 Sep;7(3):229-58. doi: 10.2174/1872213x113079990017. Recent Pat Inflamm Allergy Drug Discov. 2013. PMID: 23859695 Review.
-
[Caspase inhibition: From cellular biology and thanatology to potential clinical agents].Med Sci (Paris). 2020 Dec;36(12):1143-1154. doi: 10.1051/medsci/2020222. Epub 2020 Dec 9. Med Sci (Paris). 2020. PMID: 33296631 Review. French.
-
Caspase inhibitors: a review on recently patented compounds (2016-2023).Expert Opin Ther Pat. 2024 Oct;34(10):1047-1072. doi: 10.1080/13543776.2024.2397732. Epub 2024 Aug 29. Expert Opin Ther Pat. 2024. PMID: 39206873 Review.
-
Targeting caspases in cancer therapeutics.Biol Chem. 2013 Jul;394(7):831-43. doi: 10.1515/hsz-2013-0128. Biol Chem. 2013. PMID: 23509217 Free PMC article. Review.
Cited by
-
Effect of Nrf2 on brain injury induced by hydraulic shock via regulation of mitophagy and apoptosis.Aging (Albany NY). 2023 Nov 28;15(22):13422-13433. doi: 10.18632/aging.205250. Epub 2023 Nov 28. Aging (Albany NY). 2023. PMID: 38019476 Free PMC article.
-
Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics.Cancers (Basel). 2022 Dec 23;15(1):82. doi: 10.3390/cancers15010082. Cancers (Basel). 2022. PMID: 36612080 Free PMC article. Review.
-
Caspase Inhibition as a Possible Therapeutic Strategy for Pemphigus Vulgaris: A Systematic Review of Current Evidence.Biology (Basel). 2022 Feb 16;11(2):314. doi: 10.3390/biology11020314. Biology (Basel). 2022. PMID: 35205180 Free PMC article. Review.
-
Pyroptosis and gasdermins-Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis.Front Cell Dev Biol. 2023 Aug 17;11:1218807. doi: 10.3389/fcell.2023.1218807. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37664463 Free PMC article. Review.
-
Inhibition of the interaction between microglial adenosine 2A receptor and NLRP3 inflammasome attenuates neuroinflammation posttraumatic brain injury.CNS Neurosci Ther. 2024 Jan;30(1):e14408. doi: 10.1111/cns.14408. Epub 2023 Aug 11. CNS Neurosci Ther. 2024. PMID: 37564004 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources